CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience

BACKGROUND: Waldenström macroglobulinemia (WM) is an incurable disease and, while treatable, can develop resistance to available therapies and be fatal. Chimeric antigen receptor (CAR) T cell therapy directed against the CD19 antigen has demonstrated efficacy in relapsed or refractory B lymphoid mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomba, M Lia, Qualls, David, Monette, Sebastien, Sethi, Shenon, Dogan, Ahmet, Roshal, Mikhail, Senechal, Brigitte, Wang, Xiuyan, Rivière, Isabelle, Sadelain, Michel, Brentjens, Renier J, Park, Jae H, Smith, Eric L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852764/
https://www.ncbi.nlm.nih.gov/pubmed/35173030
http://dx.doi.org/10.1136/jitc-2021-004128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852764/
https://www.ncbi.nlm.nih.gov/pubmed/35173030
http://dx.doi.org/10.1136/jitc-2021-004128

Ejemplares similares